Solomon Moshkevich, Natera’s president of Clinical Diagnostics, sold 3,419 shares of the company’s common stock on November 2, 2026. The transactions were worth approximately $1.4 million, with sale prices ranging from $388.2001 to $416.4458 per share.
Of the shares sold, 419 were used to cover tax withholding and remittance obligations associated with the vesting of restricted stock units. Those transactions followed written instructions intended to meet the conditions of Rule 10b5-1(c). The remaining 3,000 shares were sold under a separate Rule 10b5-1 trading plan adopted by Moshkevich on November 26, 2024.
After the sales, Moshkevich directly beneficially owned 101,323 Natera shares. The stock had fallen about 10% over the previous week but remained up 96% over the past year, according to the source report. The report also cited InvestingPro’s assessment that Natera shares appeared overvalued relative to its Fair Value.
Sources: Investing.com News.